January 3, 2024 11:25 AM ESTUpdated 12:18 PM
Deals

Boehringer In­gel­heim once again turns to RNAi for new MASH ther­a­pies

Reynald Castañeda

Deputy Editor

Boehringer In­gel­heim is part­ner­ing with Chi­na-based biotech Suzhou Ri­bo Life Sci­ence and its Swe­den-based unit Ri­bo­cure Phar­ma­ceu­ti­cals to de­vel­op siR­NA ther­a­pies for meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

NICE has 'done all we can' to ne­go­ti­ate for En­her­tu cov­er­age, reaf­firms de­ci­sion not to rec­om­mend

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times